Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with its corporate origin in Japan.
read more ...

FY2019 Q1 financial results are now available.
read more ...

Completion of Payment Concerning Disposal of Treasury Shares as Restricted Share-Based Remuneration has been announced.
read more ...

2019.09.17	Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in Brazil
2019.09.12	Daiichi Sankyo Announces Launch of Oxycodone Extended Release Tablets NX “Daiichi Sankyo” for Sustained Cancer Pain Treatment in Japan
2019.09.10	Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer
2019.09.10	Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
2019.09.09	Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer
2019.09.04	Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation
2019.08.05	FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
2019.06.25	Daiichi Sankyo to transfer marketing authorization rights for four diagnostic imaging agents in Japan to GE Healthcare

2019.06.20	Daiichi Sankyo’s Japan Research Foundation for Clinical Pharmacology 12th Annual Clinical Pharmacology Research Award
2019.02.14	Daiichi Sankyo supported World Cancer Day 2019
2018.12.06	Winners of 11th Manpei Suzuki International Prize for Diabetes Research and 12th Manpei Suzuki Prize for Diabetes Care and Education Announced
2018.07.20	Daiichi Sankyo Offers Assistance to Victims of the 2018 Torrential Rain Disaster in Japan